Tech Company Financing Transactions
HI-Bio Funding Round
HI-Bio, operating out of San Francisco, secured $95 million in funding from Alpha Wave Global, Arch Venture Partners and Arkin Bio-Ventures.
Transaction Overview
Company Name
Announced On
1/4/2024
Transaction Type
Venture Equity
Amount
$95,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance felzartamab, its clinically differentiated lead therapeutic candidate, through clinical readouts in multiple indications and preparation for registrational studies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2 Tower Place 16th Floor South
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
HI-Bio� was founded on the idea that therapies for immune-mediated diseases (IMDs) have the potential to achieve better results for patients. Many IMDs stem from the dysfunction of cells that make up the immune system, including plasma cells, neutrophils, mast cells and more. These cells are responsible for critical functions and processes.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 1/4/2024: Annabella-Pump venture capital transaction
Next: 1/4/2024: Nuwa Pen venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs